Nephroprotective potential of glucagon-like peptide-1 receptor agonists
Patients with diabetes mellitus (DM), which is a key factor in the development of kidney diseases, are increasingly competing for limited healthcare resources. Diabetic kidney disease (DKD) remains a significant cause of end-stage renal failure in the patients of many countries and is also associate...
Saved in:
| Main Authors: | Minara S. Shamkhalova, Igor A. Sklyanik, Marina V. Shestakova |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2020-04-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/12379 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Association of Glucagon‐Like Peptide Agonist Therapy With Dietary Patterns in a Cross‐Sectional Cohort
by: Eric J. Brandt, et al.
Published: (2025-06-01) -
Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
by: Gagik R. Galstyan, et al.
Published: (2017-10-01) -
Physiology and pharmacology of glucagon-like peptide-1 receptor
by: D. V. Kurkin, et al.
Published: (2024-01-01) -
Therapeutic strategies, consequences and prospects of glucagon-like peptide-1 agonists
by: N.M. Bobok
Published: (2025-05-01) -
Efficacy and safety of glucagon-like peptide-1 receptor agonists therapy initiation in patients with type 2 diabetes hospitalized with coronavirus infection
by: T. N. Markova, et al.
Published: (2023-12-01)